Status:
COMPLETED
First-in-human Evaluation of [18F]CETO
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Uppsala University Hospital
British Medical Research Council
Conditions:
Primary Aldosteronism Due to Aldosterone Producing Adenoma
Primary Aldosteronism Due to Nodular Hyperplasia
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-\[18F\]fluoroethyletomidate positron emission computed tomography (\[18F\]CETO-positron emission computed tomography(PET)/compu...
Detailed Description
After receiving oral and written information about the study and its potential risks, all participants provided written informed consent. All participants underwent a screening visit 1-28 days before ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients diagnosed with adrenal incidentalomas with an concurrent overproduction of aldosterone or cortisol or no concurrent hormone production, or patients diagnosed with adrenocortical carcinoma
- For healthy volunteers inclusion criteria included no known diseases, no ongoing medication and no known adrenal anomalies.
- Exclusion Criteria for patients and healthy volunteers:
- pregnancy, age below 18, claustrophobia
Exclusion
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05361083
Start Date
September 1 2019
End Date
February 28 2022
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala University Hospital
Uppsala, Sweden, 75185